A randomized pilot trial of estrogen replacement therapy in post-menopausal women with Parkinson's disease

Parkinsonism and Related Disorders

Volumn 17, Issue 10, 2011, Pages 757-760

[No Author Info available]

Author keywords

Estrogen; Estrogen replacement therapy; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT; CONJUGATED ESTROGEN; PLACEBO;

ADULT; AGED; ARTICLE; BREAST HYPERTROPHY; BREAST TENDERNESS; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; ESTROGEN THERAPY; FEMALE; HUMAN; MENOPAUSAL SYNDROME; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; PARALLEL DESIGN; PARKINSON DISEASE; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SPOTTING; TREATMENT OUTCOME; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE;

DOUBLE-BLIND METHOD; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MIDDLE AGED; PARKINSON DISEASE; PILOT PROJECTS; POSTMENOPAUSE;

EID: 81455131682     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2011.07.007     Document Type: Article

References (12)

1. Morissette M., Di Paolo T. Effect of chronic estradiol and progesterone treatments of ovariectomized rats on brain dopamine uptake sites. Journal of Neurochemistry 1993, 60:1876-1883.
2. Currie L.J., Harrison M.B., Trugman J.M., Bennett J.P., Wooten G.F. Postmenopausal estrogen use affects risk for Parkinson disease. Archives of Neurology 2004, 61:886-888.
3. Kompoliti K. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology 2002, 58:1412-1422.
4. Tsang K.-L., Ho S.-L., Lo S.-K. Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations. Neurology 2000, 54:2292-2298.
5. Blanchet P.J., Fang J., Hyland K., Arnold L.A., Mouradian M.M., Chase T.N. Short-term effects of high-dose 17B-estradiol in postmenopausal PD patients: a cross over study. Neurology 1999, 53:91-95.
6. Nicoletti A., Arabia G., Pugliese P., Nicoletti G., Torchia G., Condino F., et al. Hormonal replacement therapy in women with Parkinson disease and levodopa-induced dyskinesia: a crossover trial. Clinical Neuropharmacology 2007, 30:276-280.
7. Strijks E., Kremer J.A.M., Horstink M.W.I.M. Effects of female sex steroids on Parkinson's disease in postmenopausal women. Clinical Neuropharmacology 1999, 22:93-97.
8. Shulman L.M., Gruber-Baldini A.L., Anderson K.E., Fishman P.S., Reich S.G., Weiner W.J. What is the clinically important difference on the United Parkinson's Disease Rating Scale?. Archives of Neurology 2010, 67:64-70.
9. Fernandez H.H., Lapane K.L. Estrogen use among nursing home residents with a diagnosis of Parkinson's disease. Movement Disorders 2000, 15:1119-1124.
10. Maki P.M., Zonderman A., Resnick S. Enhanced verbal memory in nondemented elderly women receiving hormone-replacement therapy. American Journal of Psychiatry 2001, 158:227-233.
11. Yaffe K., Vittinghoff E., Ensrud K.E., Johnson K.C., Diem S., Hanes V., et al. Effects of ultra-low dose transdermal estradiol on cognition and health-related quality of life. Archives of Neurology 2006, 63:945-950.
12. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 2002, 288:321-333. Writing Group for the Women's Health Initiative Investigators.